增殖性糖尿病视网膜病变患者玻璃体中极长链神经酰胺升高
本病例对照研究纳入25例2型糖尿病伴增殖性糖尿病视网膜病变(PDR)患者和25例年龄、性别匹配的非糖尿病对照,采用超高效液相色谱-串联质谱法测定玻璃体中多种神经酰胺水平。结果显示PDR组总神经酰胺显著高于对照组,且极长链神经酰胺(C22-C24)升高幅度大于长链神经酰胺(C16-C20)。
要点
- PDR组玻璃体总神经酰胺为18.626 ± 19.264 pmol/mg蛋白,对照组为3.524 ± 2.456 pmol/mg蛋白(P < 0.001)。
- PDR组极长链神经酰胺占76.1%,对照组以C16神经酰胺为主,占40.5%。
- 多变量线性回归显示糖尿病诊断(β = 14.5751;P = 0.0327)和较低体重指数(β = -2.1396;P = 0.0173)与极长链神经酰胺水平升高显著相关。
核心结论
- 糖尿病受试者玻璃体神经酰胺水平升高,尤其是极长链神经酰胺,可能参与糖尿病视网膜病变的发病机制。
研究设计与样本
- 病例对照研究,纳入25例2型糖尿病伴PDR患者和25例年龄、性别匹配的非糖尿病对照,均接受玻璃体切除术。
主要发现
- PDR组玻璃体总神经酰胺水平为18.626 ± 19.264 pmol/mg蛋白,对照组为3.524 ± 2.456 pmol/mg蛋白(P < 0.001)。
- 极长链神经酰胺(C22-C24)的升高幅度大于长链神经酰胺(C16-C20)。
- PDR组极长链神经酰胺占76.1%,对照组C16神经酰胺占40.5%。
- 多变量线性回归分析显示,糖尿病诊断(β = 14.5751;P = 0.0327)和较低体重指数(β = -2.1396;P = 0.0173)与极长链神经酰胺水平升高显著相关。
- 玻璃体腔注射抗VEGF导致极长链神经酰胺非显著降低(P = 0.068)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To quantitate the levels of various ceramide species in the vitreous of patients with proliferative diabetic retinopathy (PDR) and to investigate the role of vitreal ceramides in the pathogenesis of PDR. STUDY DESIGN: A case control study. METHODS: We collected vitreous samples from 25 type 2 diabetes patients with PDR and 25 age- and sex-matched nondiabetic controls undergoing vitrectomy. The levels of ceramide species (C16:0, 18:0, 20:0, 22:0, 24:1, and 24:0) were measured by ultra-high-performance liquid chromatography-tandem mass spectrometry with positive electrospray ionization mode. The correlation of baseline characteristics, blood test data, and clinical manifestation of PDR were analyzed with vitreal ceramides levels. RESULTS: The total level of ceramides was substantially higher in the PDR group than the control group (18.626 ± 19.264 versus 3.524 ± 2.456 pmol/mg protein; P < 0.001). Among ceramides of various acyl chain lengths, the increases of very-long-chain (VLC) ceramides (C22-C24) were more drastic than those of long-chain ceramides (C16-C20). In the PDR group, VLC ceramide species accounted for 76.1%, whereas in the control group, C16 ceramide predominated at 40.5%. Based on the multivariate linear regression analysis, diagnosis of diabetes (β = 14.5751; P = 0.0327) and lower body mass index (β = -2.1396; P = 0.0173) were significantly associated with higher level of VLC ceramides. Intravitreal injection of anti-VEGF leads to insignificant reduction of VLC ceramides (P = 0.068). CONCLUSIONS: Vitreal ceramide levels were elevated in diabetic subjects, especially the VLC species, which may contribute to the pathogenesis of diabetic retinopathy.
引用
- Chen YY, Yang CM, Yang CH, et al. Elevated Very-Long-Chain Ceramides in the Vitreous Humor of Patients With Proliferative Diabetic Retinopathy. Invest Ophthalmol Vis Sci. 2025. PMID: 39932474. doi:10.1167/iovs.66.2.28
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。